RiverVest News - Summer 2022

SUMMER 2022

RiverVest Hosts 22nd Annual Meeting

RiverVest held its Annual Meeting at the Ritz-Carlton St. Louis on May 3, 2022. Presenting were the RiverVest team, CEOs of five portfolio companies, and keynote speaker Dr. Alessandro Sette of the La Jolla Institute for Immunology.

Pascal Krotee, Isaac Zike, and Nancy Hong discuss building RiverVest’s Fund V portfolio. Moderated by John McKearn.

Keynote speaker Dr. Alessandro Sette presents recent data on vaccine protection against SARS-CoV-2.

RiverVest Team Updates

Isaac Zike, Ph.D. promoted to Principal. Isaac joined RiverVest in 2019 as a Senior Associate after working at Huron Consulting Group in New York.

Curtis Rother promoted to Director of Finance. Curtis joined RiverVest in 2017 as an Analyst and previously served as a Senior Analyst.

Pascal Krotee, Ph.D. joined RiverVest in February 2021 as a Senior Associate in the San Diego office after four years as an Investment Associate at Kairos Ventures.

Courtney Harris joined RiverVest as Controller in 2021. She previously served as Controller at Prolog Ventures in St. Louis.

Jeff Seitz joined RiverVest as an Analyst in January 2022 after earning a Master of Science in Finance with an emphasis in Wealth and Asset Management from Washington University in St. Louis.

Front: Kelly Cathey, John McKearn, Tom Melzer, Jay Schmelter, Nancy Hong Back: Jeff Seitz, Curtis Rother, Corrin Short, Sivan Weitzman, Pascal Krotee, Derek Rapp, Mike Berman, Isaac Zike, Courtney Harris, Andrew Kleiboeker, Karen Spilizewski. Not pictured: Niall O'Donnell

Portfolio News

Amplyx Pharmaceuticals is acquired by Pfizer.

RiverVest leads $100M Series B funding for Biolinq to develop its continuous glucose monitor.

Bluejay Therapeutics announces new team members with extensive experience in antiviral drug development.

Cardialen receives IDE approval from the FDA of its MultiPulse therapy platform.

Glycomine doses first patient in the Phase 1 study of GLM101 in PMM2-CDG.

Mirum receives FDA approval of LIVMARLI™ in Alagille Syndrome.

OncoResponse initiates Phase 1 study of OR2805 in advanced cancers.

Reneo doses its first patient in the Phase 2b STRIDE study for patients with PMM.

Scout Bio initiates multi-center clinical study of gene therapy for chronic arthritis pain in cats.

Sparrow announces FDA clearance of its IND for SPI-62 in Cushing’s disease.

Standard Bariatrics receives FDA clearance for its Titan SGS® surgical stapler.

Wugen doses first patient in the Phase 1/2 trial of WU-CART-007 for R/R T-ALL.

Xilio doses first patient with XTX101 in Phase 1/2 trial for solid tumors.

STAY CONNECTED

RiverVest Venture Partners is a leading life science venture capital firm focused on improving the lives of patients, supporting entrepreneurs, and earning the trust of investors through science, strategy, and innovation.

Visit our website